Feb 15 2010
ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s flagship product, GRASPA®, which consists of red blood cell-encapsulated L-asparaginase (L-ASP).
“We’re very interested in studying GRASPA® because of its reported reduction of L-asparaginase side effects.”
Pr. John Weinstein, Chair of the Department of Bioinformatics and Computational Biology at M.D. Anderson Cancer Center (Houston, TX) and principal investigator of the project, states “L-ASP is a standard component of leukemia chemotherapy regimens, but it’s not used yet against solid tumors due to erratic activity. We’ve identified a candidate biomarker, asparagine synthetase (ASNS) that may predict L-ASP activity against solid tumors.”
Dr. Philip Lorenzi, who leads the project, adds “We’re very interested in studying GRASPA® because of its reported reduction of L-asparaginase side effects.”
ERYtech Pharma’s Co-Founder and CEO, Dr. Yann Godfrin says “Collaboration with M. D. Anderson Cancer Center provides us the opportunity to develop a clinically-compatible biomarker assay and to rationally prescribe GRASPA® to patients who are most likely to respond. Toward that end, the M. D. Anderson’s researchers will analyze patient samples from ERYtech’s clinical trials.”
SOURCE ERYtech Pharma
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation